Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects

Clinical Pharmacology and Therapeutics
W J Elliott

Abstract

To compare the rates of discontinuation of angiotensin converting enzyme (ACE) inhibitors in patients with different racial and ethnic backgrounds. A registry from a tertiary hypertension clinic consisting of 892 patients who received their first-ever dose of ACE inhibitor therapy was examined. Surveillance for cough was prospective, systematic, and constant beginning in 1986 and routinely included a trial of sinusitis therapy, followed by withdrawal and rechallenge before discontinuation of drug. The prevalence (per 100 patients) of cough requiring discontinuation of ACE inhibitor therapy was 62 of 644 (9.6 per 100) patients among black subjects compared with six of 248 (2.4 per 100) patients among others (odds ratio, 4.0; 95% confidence interval, 1.7 to 9.1; p < 0.001). There were no significant differences in discontinuation rates across the three most commonly used ACE inhibitors: captopril (6.6%; all black subjects), enalapril (6.1%; 94% black subjects), and lisinopril (7.3%; 90% black subjects). Cough was more common among women (70% of subjects). After adjustment (by backward stepwise multiple logistic regression analysis) for baseline differences, black subjects had a relative risk of 2.58 (95% confidence interval, 1.21...Continue Reading

References

Sep 1, 1992·British Journal of Clinical Pharmacology·D ChalmersD H Lawson
Feb 1, 1992·The Annals of Pharmacotherapy·J LefebvreY Lacourcière
Jun 1, 1991·The Tohoku Journal of Experimental Medicine·U KatsumataT Takishima
May 1, 1991·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·T KakuG Inoue
Jan 1, 1991·American Journal of Hypertension·T Saruta, K Nishikawa
Aug 19, 1988·JAMA : the Journal of the American Medical Association·E E SlaterP W Ewan
Aug 1, 1985·Archives of Internal Medicine·S Sesoko, Y Kaneko
May 5, 1983·The New England Journal of Medicine·M SchapiraR W Colman
Apr 21, 1994·Drug and Therapeutics Bulletin
Feb 1, 1995·British Journal of Clinical Pharmacology·V CharlonK S Woo
Jun 1, 1995·Journal of Clinical Epidemiology·L E VisserA Bakker
Nov 1, 1994·American Journal of Hypertension·I OsS Tretli
Mar 19, 1994·Lancet·I G ChadwickA H Morice
Jun 1, 1994·The Annals of Pharmacotherapy·M N SharifG B Pylypchuk
Dec 15, 1993·Annals of Internal Medicine·N J Brown, J H Nadeau
Dec 30, 1993·The American Journal of Cardiology·H A Punzi
Mar 1, 1993·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·J L RodicioL M Ruilope
Jan 1, 1993·European Journal of Clinical Pharmacology·W K ChanJ A Critchley

❮ Previous
Next ❯

Citations

May 16, 2007·Journal of General Internal Medicine·Walid F GelladJennifer S Haas
Jun 24, 2004·Journal of General Internal Medicine·Takeshi MorimotoDavid W Bates
Jul 23, 1999·Pharmacotherapy·C A Luque, M Vazquez Ortiz
Jan 28, 2010·Acta Clinica Belgica·L D KolaJ M Krzesinski
Apr 5, 2014·Expert Opinion on Pharmacotherapy·Christos V Rizos, Moses S Elisaf
Jul 9, 2004·Current Opinion in Allergy and Clinical Immunology·Mark S Dykewicz
Oct 30, 1998·The Annals of Pharmacotherapy·G B Pylypchuk
May 8, 2001·Pharmacoepidemiology and Drug Safety·Y S KimUNKNOWN Korea Post-Marketing Surveillance Research Group
Oct 16, 2004·Journal of Evaluation in Clinical Practice·Takeshi MorimotoDavid W Bates
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Aug 2, 2007·Critical Pathways in Cardiology·Keith C Ferdinand, Annemarie M Armani
Jan 18, 2006·The Journal of Clinical Hypertension·Keith C Ferdinand, Elijah Saunders
Oct 27, 2017·Expert Opinion on Drug Safety·William J Elliott, Evgeny A Bistrika
Sep 16, 2009·Preventive Cardiology·Philip R Liebson
May 4, 2010·The Journal of Clinical Hypertension·Esosa Odigie-OkonAlix Dufresne
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·C Venkata S Ram
Jan 6, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Janice G Douglas
Dec 14, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David H G Smith
May 1, 2020·European Heart Journal·Michael BöhmIngrid Kindermann
Aug 6, 2008·Nature Clinical Practice. Nephrology·Keith C NorrisNosratola D Vaziri
Oct 26, 2011·Journal of Clinical Pharmacy and Therapeutics·M C S WongS M Griffiths

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.